Search
Adlai Nortye Ltd
ANLAdd to Watchlist
13.510USD
-0.350-2.53%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
717.07MMarket Cap
LossP/E TTM
More Details of Adlai Nortye Ltd Company
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Adlai Nortye Ltd Info
Ticker SymbolANL
Company nameAdlai Nortye Ltd
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Number of employees123
Security typeDepository Receipt
Fiscal year-endSep 29
Addressc/o PO Box 309
CityGRAND CAYMAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCayman Islands
Postal codeKY1-1104
Phone18482307430
Websitehttps://www.adlainortye.com/
Ticker SymbolANL
IPO dateSep 29, 2023
CEOBirgerson (Lars Erik)
Company Executives of Adlai Nortye Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 7
Updated: Thu, May 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VR Adviser, LLC
6.78%
Nortye International Ltd
4.92%
Nortye Talent Ltd
0.74%
UBS Financial Services, Inc.
0.26%
Deep Track Capital LP
0.07%
Other
87.23%
Shareholders
Shareholders
Proportion
VR Adviser, LLC
6.78%
Nortye International Ltd
4.92%
Nortye Talent Ltd
0.74%
UBS Financial Services, Inc.
0.26%
Deep Track Capital LP
0.07%
Other
87.23%
Shareholder Types
Shareholders
Proportion
Venture Capital
6.78%
Corporation
5.66%
Investment Advisor
0.31%
Hedge Fund
0.07%
Investment Advisor/Hedge Fund
0.02%
Other
87.16%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
13
3.40M
7.18%
+3.31M
2025Q4
8
16.26K
0.36%
--
2025Q3
8
16.26K
0.36%
-43.42K
2025Q2
7
59.68K
0.18%
+3.12K
2025Q1
5
56.56K
0.18%
-420.00
2024Q4
4
56.89K
0.20%
-6.80K
2024Q3
4
63.69K
0.19%
+4.64K
2024Q2
4
59.05K
0.20%
-1.37K
2024Q1
4
60.42K
0.20%
-3.15K
2023Q4
4
62.99K
0.15%
+14.74K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VR Adviser, LLC
3.21M
6.09%
+3.21M
--
Feb 04, 2026
Nortye International Ltd
2.33M
4.42%
+2.33M
--
Dec 31, 2024
Nortye Talent Ltd
349.27K
0.66%
+349.27K
--
Dec 31, 2024
UBS Financial Services, Inc.
1.08K
0%
-3.21K
-74.88%
Dec 31, 2025
Deep Track Capital LP
34.85K
0.07%
+34.85K
--
Dec 31, 2025
SmartHarvest Portfolios, LLC
15.09K
0.03%
+15.09K
--
Dec 31, 2025
EverSource Wealth Advisors, LLC
4.79K
0.01%
+4.08K
+566.76%
Dec 31, 2025
Bessemer Trust Company, N.A. (US)
91.00
0%
--
--
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
